Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans

Caroline A. Lee, Chun Yang, Vishal Shah, Zancong Shen, David M. Wilson, Traci M. Ostertag, Jean-Luc Girardet, Jesse Hall and Michael Gillen
Drug Metabolism and Disposition May 2018, 46 (5) 532-541; DOI: https://doi.org/10.1124/dmd.117.078220
Caroline A. Lee
Preclinical and Clinical DMPK (C.A.L., C.Y.,V.S., Z.S.), Bioanalytical (D.M.W.), Biology (T.M.O.), Chemistry (J.-L.G.), and Clinical Development (J.H.) Ardea Biosciences, Inc., San Diego, California; and Early Clinical Development, IMED Biotech Unit, Quantitative Clinical Pharmacology (M.G.) AstraZeneca LP, Gaithersburg, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chun Yang
Preclinical and Clinical DMPK (C.A.L., C.Y.,V.S., Z.S.), Bioanalytical (D.M.W.), Biology (T.M.O.), Chemistry (J.-L.G.), and Clinical Development (J.H.) Ardea Biosciences, Inc., San Diego, California; and Early Clinical Development, IMED Biotech Unit, Quantitative Clinical Pharmacology (M.G.) AstraZeneca LP, Gaithersburg, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vishal Shah
Preclinical and Clinical DMPK (C.A.L., C.Y.,V.S., Z.S.), Bioanalytical (D.M.W.), Biology (T.M.O.), Chemistry (J.-L.G.), and Clinical Development (J.H.) Ardea Biosciences, Inc., San Diego, California; and Early Clinical Development, IMED Biotech Unit, Quantitative Clinical Pharmacology (M.G.) AstraZeneca LP, Gaithersburg, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zancong Shen
Preclinical and Clinical DMPK (C.A.L., C.Y.,V.S., Z.S.), Bioanalytical (D.M.W.), Biology (T.M.O.), Chemistry (J.-L.G.), and Clinical Development (J.H.) Ardea Biosciences, Inc., San Diego, California; and Early Clinical Development, IMED Biotech Unit, Quantitative Clinical Pharmacology (M.G.) AstraZeneca LP, Gaithersburg, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David M. Wilson
Preclinical and Clinical DMPK (C.A.L., C.Y.,V.S., Z.S.), Bioanalytical (D.M.W.), Biology (T.M.O.), Chemistry (J.-L.G.), and Clinical Development (J.H.) Ardea Biosciences, Inc., San Diego, California; and Early Clinical Development, IMED Biotech Unit, Quantitative Clinical Pharmacology (M.G.) AstraZeneca LP, Gaithersburg, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Traci M. Ostertag
Preclinical and Clinical DMPK (C.A.L., C.Y.,V.S., Z.S.), Bioanalytical (D.M.W.), Biology (T.M.O.), Chemistry (J.-L.G.), and Clinical Development (J.H.) Ardea Biosciences, Inc., San Diego, California; and Early Clinical Development, IMED Biotech Unit, Quantitative Clinical Pharmacology (M.G.) AstraZeneca LP, Gaithersburg, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Luc Girardet
Preclinical and Clinical DMPK (C.A.L., C.Y.,V.S., Z.S.), Bioanalytical (D.M.W.), Biology (T.M.O.), Chemistry (J.-L.G.), and Clinical Development (J.H.) Ardea Biosciences, Inc., San Diego, California; and Early Clinical Development, IMED Biotech Unit, Quantitative Clinical Pharmacology (M.G.) AstraZeneca LP, Gaithersburg, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jesse Hall
Preclinical and Clinical DMPK (C.A.L., C.Y.,V.S., Z.S.), Bioanalytical (D.M.W.), Biology (T.M.O.), Chemistry (J.-L.G.), and Clinical Development (J.H.) Ardea Biosciences, Inc., San Diego, California; and Early Clinical Development, IMED Biotech Unit, Quantitative Clinical Pharmacology (M.G.) AstraZeneca LP, Gaithersburg, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Gillen
Preclinical and Clinical DMPK (C.A.L., C.Y.,V.S., Z.S.), Bioanalytical (D.M.W.), Biology (T.M.O.), Chemistry (J.-L.G.), and Clinical Development (J.H.) Ardea Biosciences, Inc., San Diego, California; and Early Clinical Development, IMED Biotech Unit, Quantitative Clinical Pharmacology (M.G.) AstraZeneca LP, Gaithersburg, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Information

vol. 46 no. 5 532-541
DOI 
https://doi.org/10.1124/dmd.117.078220
PubMed 
29490903

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0090-9556
Online ISSN 
1521-009X
History 
  • Received August 24, 2017
  • Accepted February 23, 2018
  • Published online April 4, 2018.

Article Versions

  • Earlier version (February 28, 2018 - 06:37).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics

Author Information

  1. Caroline A. Lee,
  2. Chun Yang,
  3. Vishal Shah,
  4. Zancong Shen,
  5. David M. Wilson,
  6. Traci M. Ostertag,
  7. Jean-Luc Girardet,
  8. Jesse Hall, and
  9. Michael Gillen
  1. Preclinical and Clinical DMPK (C.A.L., C.Y.,V.S., Z.S.), Bioanalytical (D.M.W.), Biology (T.M.O.), Chemistry (J.-L.G.), and Clinical Development (J.H.) Ardea Biosciences, Inc., San Diego, California; and Early Clinical Development, IMED Biotech Unit, Quantitative Clinical Pharmacology (M.G.) AstraZeneca LP, Gaithersburg, Maryland
  1. Address correspondence to:
    Dr. Caroline A. Lee, Ardea Biosciences, Inc., 9390 Towne Centre Drive, San Diego, CA 92121. E-mail: dmpksolutions.clee{at}gmail.com
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: February 2018 to March 2023

AbstractFullPdf
Feb 201885136
Mar 20186335215
Apr 20183126584
May 20181281541
Jun 201892919
Jul 2018651240
Aug 201859629
Sep 201852432
Oct 201864222
Nov 201860819
Dec 201843712
Jan 201933218
Feb 20191021317
Mar 201969014
Apr 2019163423
May 2019153637
Jun 2019101312
Jul 2019183439
Aug 2019125231
Oct 2019133723
Nov 2019173530
Dec 2019173524
Jan 2020194036
Feb 202093322
Mar 202074130
May 202022741
Jun 202025065
Jul 202072934
Aug 202063022
Sep 202072745
Oct 202054335
Nov 202012626
Dec 202052544
Jan 2021112435
Feb 2021101921
Mar 202172440
Apr 202152342
May 202172420
Jun 202141719
Jul 202131825
Aug 202132450
Sep 202162626
Oct 202137643
Nov 202153848
Dec 202124529
Jan 202243815
Feb 202222615
Mar 202212726
Apr 202252112
May 202233824
Jun 202253322
Jul 202244163
Aug 202222618
Sep 202221921
Oct 202231926
Nov 202232337
Dec 202231631
Jan 202332415
Feb 202322631
Mar 202301312

PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 46 (5)
Drug Metabolism and Disposition
Vol. 46, Issue 5
1 May 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Verinurad Human Metabolism

Caroline A. Lee, Chun Yang, Vishal Shah, Zancong Shen, David M. Wilson, Traci M. Ostertag, Jean-Luc Girardet, Jesse Hall and Michael Gillen
Drug Metabolism and Disposition May 1, 2018, 46 (5) 532-541; DOI: https://doi.org/10.1124/dmd.117.078220

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Verinurad Human Metabolism

Caroline A. Lee, Chun Yang, Vishal Shah, Zancong Shen, David M. Wilson, Traci M. Ostertag, Jean-Luc Girardet, Jesse Hall and Michael Gillen
Drug Metabolism and Disposition May 1, 2018, 46 (5) 532-541; DOI: https://doi.org/10.1124/dmd.117.078220
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Metabolic enzymes in nintedanib metabolism
  • Mechanism of AO Inactivation by Hydralazine
  • Warfarin PBPK modeling with target binding
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics